Epigenomics reported H1/2019 revenues of €679k, down 12% YoY and below our €1.4m estimate, due largely to a reduction in licensing revenue resulting from termination of the collaboration with Chinese partner BioChain. Importantly, the latter was partly offset by an 84% YoY increase in product revenue from Epi proColon, and we expect solid underlying growth momentum to continue throughout H2/2019E. Management adjusted FY2019 financial outlook to €2.0m - €4.0m (from €3.0m - €6.0m), due to the dela ....
16 Aug 2019
Underlying growth momentum continues
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Underlying growth momentum continues
Epigenomics AG (0QXH:LON) | 0 0 0.0% | Mkt Cap: 24.5m
- Published:
16 Aug 2019 -
Author:
Martin Piehlmeier -
Pages:
9
Epigenomics reported H1/2019 revenues of €679k, down 12% YoY and below our €1.4m estimate, due largely to a reduction in licensing revenue resulting from termination of the collaboration with Chinese partner BioChain. Importantly, the latter was partly offset by an 84% YoY increase in product revenue from Epi proColon, and we expect solid underlying growth momentum to continue throughout H2/2019E. Management adjusted FY2019 financial outlook to €2.0m - €4.0m (from €3.0m - €6.0m), due to the dela ....